Compare IMXI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | BCYC |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 360.7M |
| IPO Year | 2016 | 2019 |
| Metric | IMXI | BCYC |
|---|---|---|
| Price | $15.90 | $5.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $15.00 | $13.90 |
| AVG Volume (30 Days) | 318.0K | ★ 593.0K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $319,601,000.00 | N/A |
| Revenue This Year | $0.83 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $14.72 | ★ N/A |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $8.58 | $4.24 |
| 52 Week High | $15.90 | $9.55 |
| Indicator | IMXI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 69.20 | 53.49 |
| Support Level | $15.78 | $5.03 |
| Resistance Level | $15.90 | $5.90 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 96.00 | 75.68 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.